NCT00947167 2017-03-03A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine TumorsStanford UniversityPhase 2 Terminated4 enrolled 5 charts
NCT01121939 2016-02-05Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine CancersSCRI Development Innovations, LLCPhase 2 Completed43 enrolled 9 charts